Increase in Types 1 and 2 Diabetes Seen in U.S. Youth During Pandemic
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Sept. 26, 2023 -- The incidence of type 1 and type 2 diabetes increased among U.S. youth during the COVID-19 pandemic, according to a study published online Sept. 21 in JAMA Network Open.
Matthew T. Mefford, Ph.D., from Kaiser Permanente Southern California in Pasadena, and colleagues examined diabetes incidence rates among youth (from birth to 19 years) in the United States using data from Kaiser Permanente Southern California between Jan. 1, 2016, and Dec. 31, 2021. The age- and sex-standardized annual and quarterly incidence rates were calculated per 100,000 person-years (PYs) for type 1 and type 2 diabetes.
The researchers found 1,200, 1,100, and 63 patients had type 1 diabetes, type 2 diabetes, and other diabetes, respectively, between 2016 and 2021. The incidence of type 1 diabetes increased from 18.5 to 22.4 per 100,000 PYs in 2016-2019 to 2020-2021, with increased incidence rate ratios (IRRs) for those aged 10 to 19 years, males, and Hispanics. Type 2 diabetes incidence increased from 14.8 to 24.7 per 100,000 PYs from 2016-2019 to 2020-2021, with increased IRRs among those aged 10 to 19 years, males and females, and those with Black, Hispanic, and other/unknown race and ethnicity.
"Future research to understand potential underlying physiologic and behavioral risk factors before and during the pandemic among individuals at high risk for incident diabetes is warranted," the authors write.
Mefford disclosed receiving grants from Merck, Sharp, & Dohme.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Further Support and Information on COVID-19
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.